[{"arm_notes": "", "treatment_id": null, "treatment_name": "Vaccine group:Three doses of experimental vaccine at the schedule of day 0; 28; 56;Placebo group:Three doses of placebo at the schedule of day 0; 28; 56;Vaccine(China cohort; for immunogenicity bridging):Three doses of experimental vaccine at the schedule of day 0; 28; 56;", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Vaccine group:Three doses of experimental vaccine at the schedule of day 0; 28; 56", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Placebo group:Three doses of placebo at the schedule of day 0; 28; 56; Vaccine(China cohort", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "for immunogenicity bridging):Three doses of experimental vaccine at the schedule of day 0; 28; 56;", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1088, "treatment_name": "Recombinant sars-cov-2 vaccine (cho cell)", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "China cohort, for immunogenicity bridging", "treatment_id": 1088, "treatment_name": "Recombinant sars-cov-2 vaccine (cho cell)", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]